Current regulatory landscape on fast-track pathway for IVDs under COVID-19 heath emergency in India

Sella Senthil Marimuthu Gowthamarajan Kuppusamy Arun Radhakrishnan Jithenthiran Saravanan Indhumathi Thirugnanasambandham   

Open Access   

Published:  Jun 19, 2022

Abstract

The novel coronavirus (2019-nCoV) pandemic’s global regulatory authorities are issuing provisional market authorization to current public health for timely detection of COVID-19 infections based on the analytical performance data, limited clinical performance data, and manufacturers’ declarations. Importers, local manufacturers, government procurement agencies, and other stakeholders should be made aware of the regulatory process for market authorization of COVID-19 in vitro diagnostic (IVD) kits in India. The objective is to study in detail about COVID-19 IVD guidelines. Concentrating on the recent updates in COVID-19 IVD guidelines, we analyze the necessity for India to become efficient in manufacturing SARS-CoV-2 IVDs. In India, Central Drugs Standard Control Organization (CDSCO) coordination with The Indian Council of Medical Research (ICMR) is committed to ensuring the rapid availability of diagnostic tests for COVID-19. To address the urgent need for timely detection of COVID-19 infection, it is important to scale-up the testing capacity to maximum possible levels according to the CDSCO interim licensing process. This has helped to timely expand the variety of quality diagnostic tests available in India. The regulatory tools described in this article are made based on a comparison of data available on the procedure, followed by other major countries under the health emergency without compromising on the quality of the product within the existing provisions given in the Drugs and Cosmetic Act and Medical Devices Rules 2017.


Keyword:     Provisional market authorization analytical performances data COVID-19 expedited review IVDs.


Citation:

Marimuthu SS, Kuppusamy G, Radhakrishna A, Saravanan J, Thirugnanasambandham I. Current regulatory landscape on fast-track pathway for IVDs under COVID-19 heath emergency in India. J Appl Pharm Sci, 2022; 12(07):078–087.

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text

Reference

Applications for medical devices under the Interim Order for use in relation to COVID-19: guidance document. Government of Canada, India. Available via https://www.canada.ca/en/health-canada/services/ drugs-health-products/drug-products/announcements/interim-orderimportation-sale-medical-devices-covid-19/guidance-medical-deviceapplications.html

Bhave AC. Indian regulatory update during the COVID-19 pandemic. Perspect Clin Res, 2020; 11(3):132. https://doi.org/10.4103/picr.PICR_182_20

Central Drugs Standard Control Organization. Government of India, India. Available via https://cdsco.gov.in/opencms/opencms/en/ Notifications/Public-Notices/

Das P, Mondal S, Pal S, Roy S, Vidyadharan A, Dadwal R, Bhattacharya S, Mishra DK, Chandy M., 2021 COVID diagnostics by molecular methods: a systematic review of nucleic acid-based testing systems. Indian J Med Microbiol, 2021; 39(3):271-8. https://doi.org/10.1016/j.ijmmb.2021.05.012

Health-Canada. Guidance document-applications for medical devices under the Interim Order for use in relation to COVID-19, Government of Canada, pp 1-25.

Health Sciences Authority (HSA). HSA Expedites approval of COVID-19 diagnostic tests in Singapore via provisional authorisation, Qual tech: medical device regulatory & CRO, Singapore, pp 1-7, 202.

Health Canada's regulatory response to COVID-19: access to health products. Government of Canada, Canada. Available via https:// www.canada.ca/en/health-canada/services/drugs-health-products/covid19- industry/regulatory-response-health-product-access.html

Indian Council of Medical Research (ICMR). Validation of SARSCOV2 diagnostic commodities: acceptance criteria, p 1, 202. Available via https://www.icmr.gov.in/pdf/covid/kits/Acceptance_Criteria_SARSCoV2_ diagnostic/_commodities_10092020.pdf (Accessed 9 October 2020).

In-vitro Diagnostics. Central Drugs Standard Control Organization. Government of India, India. Available via https://cdsco.gov. in/opencms/opencms/en/Medical-Device-Diagnostics/InVitro-Diagnostics/

Kits Validation & Batching Testing. ICMR, New Delhi, India. Available via https://www.icmr.gov.in/ckitevaluation.html

Matheeussen V, Corman VM, Mantke OD, McCulloch E, Lammens C, Goossens H, Niemeyer D, Wallace PS, Klapper P, Niesters HG, Drosten C. International external quality assessment for SARSCoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020. Euro Surveilll, 2020; 25(27):2001223. https://doi.org/10.2807/1560-7917.ES.2020.25.27.2001223

Medicines & Healthcare Products Regulatory Agency (MHRA). Specification criteria for serology point of care tests and self-tests, pp 1-12, 2020.

Medical devices for uses related to COVID-19. Government of Canada, India. Available via https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19industry/medicaldevices/about. html#_Expedited_authorization_path

New Medical Device Rules. Ministry of Health and Family Welfare in the Official Gazette of India, New Delhi, India, 2017.

Petrillo M, Querci M, Tkachenko O, Siska IR, Ben E, AngersLoustau A, Bogni A, Brunetto A, Fabbri M, Garlant L, Lievens A. Munoz A, Paracchini V, Pietretti D, Puertas-Gallardo A, Raffael B, Sarno E, Tregoat V, Zaro F, Van den Eede G. The EU one-stop-shop collection of publicly available information on COVID-19 in vitro diagnostic medical devices. F1000 Res, 2020; 9:1296. https://doi.org/10.12688/f1000research.27308.1

Rapid Antigen Test Kits for COVID-19 (Oropharyngeal / Nasopharyngeal swabs). ICMR, India. Available viahttps://www.icmr. gov.in/pdf/covid/kits/archive/List_of_rapid_antigen_kits_11022021.pdf (Accessed 2 November 2021)

US Department of Health and Human Services Food and Drug Administration, Center for Devices and Radiological Health. Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency, Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturers, and Food and Drug Administration Staff, pp 1-41, 2020.

US-FDA. Bio-Rad Reliance SARS-CoV-2/FluA/FluB RT-PCR assay kit, emergency use authorization. EUA202965,, pp 1-8, 2021.

Validation Kit Portal. ICMR, India. Available via https:// cvtestkit.icmr.org.in/login.php

Article Metrics

0 Absract views 0 PDF Downloads 0 Total views

   Abstract      Pdf Download

Related Search

By author names

Citiaion Alert By Google Scholar

Name Required
Email Required Invalid Email Address

Comment required